Page 105 - ITPS-8-3

INNOSC Theranostics and
Pharmacological Sciences Biomarkers for early heart risks in pre-eclampsia

novel biomarkers in large, diverse populations, and explore 6. Chappell LC, Cluver CA, Kingdom J, Tong S. Pre-eclampsia.
their potential to guide targeted interventions; (ii) enhance Lancet. 2021;398:341-354.
the accessibility and affordability of innovative tools in doi: 10.1016/S0140-6736(20)32335-7
low- and middle-income countries; and (iii) investigate the 7. Hallum S, Basit S, Kamper-Jørgensen M, Sehested TSG,
long-term CV outcomes in women with a history of pre- Boyd HA. Risk and trajectory of premature ischaemic
eclampsia using advanced diagnostics. cardiovascular disease in women with a history of pre-
eclampsia: A nationwide register-based study. Eur J Prev
Acknowledgment Cardiol. 2023;30(6):506-516.
The authors acknowledge the ongoing efforts in research doi: 10.1093/eurjpc/zwad003
and clinical advancements in maternal and CV health.
8. Phipps EA, Thadhani R, Benzing T, Karumanchi SA. Pre-
Funding eclampsia: Pathogenesis, novel diagnostics and therapies.
Nat Rev Nephrol. 2019;15(5):275-289.
None.
doi: 10.1038/s41581-019-0119-6. Erratum in: Nat Rev
Conflict of interest Nephrol. 2019;15(6):386. doi: 10.1038/s41581-019-0156-1
9. Benschop L, Duvekot JJ, Roeters Van Lennep JE. Future
The authors declare no competing interests. risk of cardiovascular disease risk factors and events in
women after a hypertensive disorder of pregnancy. Heart.
Author contributions 2019;105(16):1273-1278.
Conceptualization: All authors doi: 10.1136/heartjnl-2018-313453
Writing–original draft: Abhishek Gupta 10. Lim S, Li W, Kemper J, Nguyen A, Mol BW, Reddy M.
Writing–review & editing: All authors
Biomarkers and the prediction of adverse outcomes in
Ethics approval and consent to participate preeclampsia: A systematic review and meta-analysis. Obstet
Gynecol. 2021;137:72-81.
Not applicable. doi: 10.1097/AOG.0000000000004149
Consent for publication 11. Zeisler H, Llurba E, Chantraine F, et al. Predictive value of the
sFlt-1: PlGF ratio in women with suspected preeclampsia.
Not applicable. N Engl J Med. 2016;374(1):13-22.

Availability of data doi: 10.1056/NEJMoa1414838
Not applicable. 12. Hauge MG, Damm P, Kofoed KF, et al. Early coronary
atherosclerosis in women with previous preeclampsia. J Am
References Coll Cardiol. 2022;79(23):2310-2321.

1. Booker WA. Hypertensive disorders of pregnancy. Clin doi: 10.1016/j.jacc.2022.03.381
Perinatol. 2020;47:817-833. 13. MacDonald TM, Walker SP, Hannan NJ, Tong S,
doi: 10.1016/j.clp.2020.08.011 Kaitu’u-Lino TJ. Clinical tools and biomarkers to predict
preeclampsia. EBioMedicine. 2022;75:103780.
2. Khedagi AM, Bello NA. Hypertensive disorders of
pregnancy. Cardiol Clin. 2021;39:77-90. doi: 10.1016/j.ebiom.2021.103780
14. Benny PA, Alakwaa FM, Schlueter RJ, Lassiter CB,
doi: 10.1016/j.ccl.2020.09.005
Garmire LX. A review of omics approaches to study
3. Stuart JJ, Tanz LJ, Cook NR, et al. Hypertensive disorders of preeclampsia. Placenta. 2020;92:17-27.
pregnancy and 10-year cardiovascular risk prediction. J Am
Coll Cardiol. 2018;72:1252-1263. doi: 10.1016/j.placenta.2020.01.008
15. Zhang B, Schmidlin T. Recent advances in cardiovascular
doi: 10.1016/j.jacc.2018.05.077
disease research driven by metabolomics technologies in the
4. Sutton ALM, Harper LM, Tita ATN. Hypertensive disorders in context of systems biology. NPJ Metab Health Dis. 2024;2:25.
pregnancy. Obstet Gynecol Clin North Am. 2018;45:333-347.
doi: 10.1038/s44324-024-00028-z
doi: 10.1016/j.ogc.2018.01.012
16. Magro D, Venezia M, Balistreri CR. The omics technologies
5. Dimitriadis E, Rolnik DL, Zhou W, et al. Pre-eclampsia. Nat and liquid biopsies: Advantages, limitations, applications.
Rev Dis Primers. 2023;9:8. Med Omics. 2024;11:100039.
doi: 10.1038/s41572-023-00417-6 doi: 10.1016/j.meomic.2024.100039

Volume 8 Issue 3 (2025) 99 doi: 10.36922/itps.7839